Literature DB >> 14983981

NC-531 (Neurochem).

Hugo Geerts1.   

Abstract

NC-531 is a sulfated glycosaminoglycan mimetic that inhibits amyloid plaque formation, and is under development by Neurochem for the potential treatment of Alzheimer's disease. Phase I clinical trials of NC-531 were ongoing in November 1999, and by October 2002 phase II trials were underway.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14983981

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  8 in total

1.  Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon.

Authors:  Daniel D Christensen
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

2.  Bivalent ligands targeting multiple pathological factors involved in Alzheimer's disease.

Authors:  Kai Liu; Ronak Gandhi; Jiangmin Chen; Shijun Zhang
Journal:  ACS Med Chem Lett       Date:  2012-09-11       Impact factor: 4.345

Review 3.  Current treatment of mild cognitive impairment and Alzheimer's disease.

Authors:  David S Knopman
Journal:  Curr Neurol Neurosci Rep       Date:  2006-09       Impact factor: 5.081

4.  Ascidians: an invertebrate chordate model to study Alzheimer's disease pathogenesis.

Authors:  Michael J Virata; Robert W Zeller
Journal:  Dis Model Mech       Date:  2010-03-02       Impact factor: 5.758

5.  Transglutaminases Derived from Astrocytes Accelerate Amyloid β Aggregation.

Authors:  Kenji Kawabe; Katsura Takano; Mitsuaki Moriyama; Yoichi Nakamura
Journal:  Neurochem Res       Date:  2017-04-09       Impact factor: 3.996

6.  An uncommon cause of bilateral pulmonary nodules in a long-term smoker.

Authors:  Kumar Gaurav; Mukta Panda
Journal:  J Gen Intern Med       Date:  2007-09-12       Impact factor: 5.128

7.  Present and prospective clinical therapeutic regimens for Alzheimer's disease.

Authors:  Mustafa M Husain; Kenneth Trevino; Haroon Siddique; Shawn M McClintock
Journal:  Neuropsychiatr Dis Treat       Date:  2008-08       Impact factor: 2.570

Review 8.  Pharmacotherapeutic targets in Alzheimer's disease.

Authors:  Yif'at Biran; Colin L Masters; Kevin J Barnham; Ashley I Bush; Paul A Adlard
Journal:  J Cell Mol Med       Date:  2008-11-18       Impact factor: 5.310
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.